Ubs Group Ag Mereo Biopharma Group PLC Call Options Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MREO
# of Institutions
100Shares Held
112MCall Options Held
1MPut Options Held
668K-
Janus Henderson Group PLC London, X022.7MShares$52.5 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$35.4 Million0.99% of portfolio
-
Mangrove Partners New York, NY8.64MShares$20 Million3.05% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.82MShares$18.1 Million1.11% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$15.5 Million0.38% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $289M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...